SMURF1 E3 ligase inhibitor

SI-8072

SMURF1 E3 ligase inhibitor, >98% (HPLC)

IUPAC Name : 1-(2-Chloro-4-cyclopropylphenyl)-N-(2-(2-fluorophenyl)-1,5-dimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-5-methyl-1H-1,2,3-triazole-4-carboxamide

Price And Availability
Pack Size	Price in USD	Add To Shopping Cart	Availability	Shipping Status
5MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
10MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
25MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
50MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
100MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026

Applications : This is a novel small‑molecule SMURF1 E3 ligase inhibitor developed for pulmonary arterial hypertension (PAH), a severe condition with major unmet need. It demonstrates potent SMURF1 inhibition, good oral pharmacokinetics in rats, and significant efficacy in a rodent PAH model, underscoring SMURF1 as a promising new therapeutic target for PAH.

References : Shaw E. D. et al.: J. Med. Chem., 66(12), 8130-8139, 2023.

Storage : Keep container tightly closed under nitrogen or argon and refrigerate for long-term shelf life.

Caution : In case of contact with skin or eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing and gloves.